Overview

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

Status:
Completed

Trial end date:
2021-06-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).

Phase:

Phase 3

Details

Lead Sponsor:

Allergan

Treatments:

Lubricant Eye Drops